When institutional reliability matters: the story of di-ethylene glycol

India's recurring struggle with Di-ethylene Glycol (DEG) contamination in pharmaceutical products is a poignant narrative that underscores critical deficiencies in public health infrastructure and regulatory oversight. This issue, which has tragically resurfaced multiple times over the past four decades, highlights a systemic failure to safeguard citizens from preventable harm, despite India being a global pharmaceutical powerhouse, often dubbed the 'pharmacy of the world'. Di-ethylene Glycol (DEG) is a highly toxic chemical, often used as an industrial solvent, antifreeze, or brake fluid. Its sweet taste and viscous texture make it a cheap, illicit substitute for pharmaceutical-grade solvents like propylene glycol or glycerine in liquid oral formulations, particularly cough syrups for children. Ingestion of even small amounts can lead to severe acute kidney injury, neurological damage, and ultimately, death. The symptoms often mimic other illnesses, making diagnosis difficult and delaying appropriate treatment. India's tragic encounters with DEG trace back decades. One of the earliest documented incidents occurred in 1973 in Chennai (then Madras), where contaminated cough syrup led to numerous child deaths. Subsequent incidents have marred the nation's public health record, including the 1986 Mumbai incident, the 1988 Delhi incident, and more recently, the 2020 Jammu and Kashmir tragedy where 12 children died after consuming contaminated cough syrup. Globally, similar incidents have occurred, such as the 1937 'Elixir Sulfanilamide' tragedy in the US, which prompted the creation of the FDA's regulatory authority. The common thread in all these incidents is the failure of quality control checks, often driven by manufacturers looking to cut costs by using cheaper, toxic raw materials. The key stakeholders in this crisis are numerous and interconnected. At the forefront are the **pharmaceutical manufacturers** who, driven by unethical practices or negligence, either directly use contaminated raw materials or fail to implement stringent quality control measures. The **raw material suppliers** also bear significant responsibility for providing substandard or adulterated ingredients. Crucially, **government regulatory bodies** — primarily the Central Drugs Standard Control Organisation (CDSCO) at the national level and State Drug Control Authorities at the state level — are responsible for licensing, inspecting manufacturing facilities, testing drug samples, and enforcing quality standards. Their failure to conduct thorough inspections, detect adulteration, and take swift punitive action is a glaring weakness. **Healthcare professionals** (doctors, pharmacists) are also stakeholders, as they prescribe and dispense these medicines, often unaware of the underlying contamination. Finally, the **public/consumers** are the ultimate victims, their trust betrayed and lives endangered. This recurring problem has profound significance for India. Firstly, it represents a grave **public health crisis**, directly impacting the fundamental 'Right to Life' enshrined in **Article 21** of the Indian Constitution, which implicitly includes the right to health and safe medical care. The state's duty to improve public health is also outlined in **Article 47** (Directive Principles of State Policy). Secondly, these incidents severely **tarnish India's reputation** as the 'pharmacy of the world' and a reliable supplier of affordable, quality medicines, especially generic drugs. This can have significant **economic repercussions**, impacting pharmaceutical exports, foreign investment, and the 'Make in India' initiative. The global outcry following recent incidents involving Indian-made cough syrups in Gambia and Uzbekistan further amplified these concerns, leading to international scrutiny and potential trade barriers. Thirdly, it exposes deep-seated **governance failures** in drug regulation, enforcement, and accountability, eroding public trust in government institutions. The primary legal framework governing this sector is the **Drugs and Cosmetics Act, 1940, and Rules, 1945**, which mandates standards for manufacturing, import, sale, and distribution of drugs. The **Consumer Protection Act** also provides recourse for victims. The historical context reveals a pattern of reactive measures rather than proactive prevention. Each tragedy elicits public outrage, promises of stricter action, and often, new committees or guidelines, but the underlying systemic weaknesses persist. This suggests a lack of sustained institutional capacity, political will, and ethical commitment across the supply chain. Looking ahead, the future implications are clear: India must urgently bolster its regulatory framework. This involves strengthening the CDSCO and State Drug Control Authorities with more resources, skilled personnel, advanced testing laboratories, and greater autonomy. There is a need for more frequent and unannounced inspections, stringent raw material verification, and prompt prosecution of offenders under the **Indian Penal Code** for culpable homicide or grievous hurt. Implementing robust pharmacovigilance systems and mandatory track-and-trace mechanisms for pharmaceutical products could enhance accountability. Furthermore, international collaboration and adherence to global manufacturing standards (like WHO-GMP) are crucial to maintain India's standing in the global pharmaceutical market. Without fundamental reforms and a renewed commitment to institutional reliability, the specter of DEG contamination will continue to haunt India's public health landscape, undermining both lives and reputation.